Emcure Pharmaceuticals Analyst Review May 2026
- May 19, 2026
- Posted by: Neeraj Pandey
- Category: News
This Emcure Pharmaceuticals analyst review for May 2026 covers the key data investors need for EMCURE at its current price of Rs 1,685.00. Emcure Pharmaceuticals (NSE: EMCURE) is a leading Indian pharma company with a market capitalisation of approximately Rs 11,000 crore, known for its gynaecology, HIV, and cardiology branded formulations. The analyst consensus target of Rs 2,100 implies meaningful upside, and this Emcure Pharmaceuticals analyst review examines technical levels, business segments, valuation, and key risks for EMCURE through FY27.
Click Here – Get Free Investment Predictions
Emcure Pharmaceuticals Company Snapshot May 2026
Emcure’s branded formulations in gynaecology (Zurig, Cycloreg) are market leaders. The HIV business (Hetero JV) and international operations in Brazil, Canada, and Europe add meaningful diversification to this branded-first pharma business. The table below summarises the key data referenced in this Emcure Pharmaceuticals analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | EMCURE |
| Sector | Pharmaceuticals – Branded and Global |
| CMP (May 2026) | Rs 1,685.00 |
| 52 Week High | Rs 1,830.00 |
| 52 Week Low | Rs 1,040.00 |
| Market Cap | Rs 11,000 Crore |
| Trailing P/E | 28x |
| Analyst Consensus Target | Rs 2,100 |
| Bull Case Target | Rs 2,600 |
| Bear Case Target | Rs 1,500 |
Analyst Insight in This Emcure Pharmaceuticals Analyst Review
Senior Research Analyst Ankit Jaiswal flags Emcure Pharmaceuticals as a stock to watch in May 2026. At Rs 1,685.00, Ankit Jaiswal identifies key support in the Rs 1061 to Rs 1601 band and resistance near Rs 1786. He suggests watching Emcure Pharmaceuticals for a potential move toward Rs 2,100, subject to Pharmaceuticals – Branded and Global sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Emcure Pharmaceuticals analyst review and does not constitute a trade recommendation.
Technical Analysis in This Emcure Pharmaceuticals Analyst Review
At Rs 1,685.00, EMCURE is trading within its 52-week band of Rs 1,040.00 to Rs 1,830.00. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 1061 to Rs 1601 band while resistance is seen in the Rs 1786 to Rs 1892 zone. A sustained move above Rs 1786 could open the path toward the analyst consensus target of Rs 2,100 as outlined in this Emcure Pharmaceuticals analyst review.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 1061 to Rs 1601 – investors tracking this Emcure Pharmaceuticals analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for EMCURE.
- Resistance Zone: Rs 1786 to Rs 1892 – a sustained close above Rs 1786 would be a positive breakout signal worth flagging in this Emcure Pharmaceuticals analyst review.
- Medium-Term Target: The analyst consensus of Rs 2,100 represents the base-case upside scenario in this Emcure Pharmaceuticals analyst review.
Business Segment Analysis
India Branded Formulations (Gynaecology, Cardiology)
This is the primary revenue and margin driver for Emcure Pharmaceuticals, directly supporting the earnings trajectory toward the consensus target of Rs 2,100.
HIV Treatment Drugs (Hetero JV Partnership)
This segment adds scale and diversification to Emcure Pharmaceuticals’s business model and is a meaningful EPS contributor through FY27 and FY28.
International Operations (Brazil, Canada, Europe)
This represents the medium-term growth frontier for Emcure Pharmaceuticals and a key re-rating catalyst over the next 12 to 24 months.
Valuation in This Emcure Pharmaceuticals Analyst Review
At Rs 1,685.00, Emcure Pharmaceuticals trades at a trailing P/E of 28x. This Emcure Pharmaceuticals analyst review presents three scenarios: a bull case of Rs 2,600 on strong earnings delivery and sector tailwinds, a base case of Rs 2,100 at analyst consensus, and a bear case of Rs 1,500 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Emcure Pharmaceuticals analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 2,600 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 2,100 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 1,500 | Earnings miss or macro headwinds |
Trade Outlook for Emcure Pharmaceuticals
Based on the technical and fundamental analysis in this Emcure Pharmaceuticals analyst review, investors might watch EMCURE near the support zone of Rs 1061 to Rs 1601 for potential opportunities. A flag above Rs 1786 could suggest improving momentum toward Rs 2,100. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Emcure Pharmaceuticals in FY27
A well-rounded Emcure Pharmaceuticals analyst review must assess downside risks. Key risks for Emcure Pharmaceuticals include a macro slowdown affecting Pharmaceuticals – Branded and Global sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in EMCURE.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Emcure Pharmaceuticals Analyst Review Verdict for 2026
This Emcure Pharmaceuticals analyst review concludes that at Rs 1,685.00, EMCURE offers a defined risk-reward with a consensus target of Rs 2,100. The 52-week range of Rs 1,040.00 to Rs 1,830.00 provides context on the current entry point. Use this Emcure Pharmaceuticals analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on EMCURE.
Frequently Asked Questions: Emcure Pharmaceuticals Analyst Review 2026
What is the analyst target for Emcure Pharmaceuticals in 2026?
The analyst consensus target is Rs 2,100, with a bull case of Rs 2,600 and a bear case of Rs 1,500. This Emcure Pharmaceuticals analyst review recommends monitoring Q1 FY27 earnings for confirmation.
Is Emcure Pharmaceuticals a good investment at Rs 1,685.00?
At Rs 1,685.00 with a P/E of 28x and a consensus target of Rs 2,100, this Emcure Pharmaceuticals analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Branded and Global sector. Always consult a SEBI-registered advisor before investing.
What is Emcure Pharmaceuticals’s 52-week high and low?
The 52-week high is Rs 1,830.00 and the 52-week low is Rs 1,040.00. At Rs 1,685.00, EMCURE is positioned within this range as detailed in this Emcure Pharmaceuticals analyst review.
What are the key risks for Emcure Pharmaceuticals?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Branded and Global sector, all assessed in this Emcure Pharmaceuticals analyst review.
Where can I track live data for Emcure Pharmaceuticals?
Track Emcure Pharmaceuticals’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Emcure Pharmaceuticals analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
